Granted Patent
B2
US 12,448,432 · App. 17/721,647 · Granted Oct 21, 2025
Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof
Inventors:
Yihong Yao (Rockville, MD); Yanfeng Li (Hong Kong, CN); Yutian Wei (Hong Kong, CN); Shigui Zhu (Rockville, MD); Xin Yao (Rockville, MD); Jiaqi Huang (Rockville, MD)
Assignee:
AbelZeta Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention provides a combined chimeric antigen receptor targeting CD19 and CD20 and application thereof. Specifically, the present invention provides a combined chimeric antigen receptor targeting CD19 and CD20, which comprises a scFv targeting CD19 and CD20, a hinge region, a transmembrane region, and an intracellular signaling domain. The present invention provides a nucleic acid molecule encoding the chimeric antigen receptor and a corresponding expression vector, a CAR-T cell, and applications thereof. The experimental results show that the chimeric antigen receptor provided by the present invention shows extremely high killing ability against tumor cells. The chimeric antigen receptor of the present invention targets CD19 and/or CD20 positive cells and can be used to treat CD19 and/or CD20 positive B-cell lymphoma, leukemia and other diseases.
Claims (10)
1. A nucleic acid encoding a bispecific chimeric antigen receptor (CAR), wherein the bispecific CAR comprises an amino acid sequence set forth in SEQ ID NO: 16, and wherein the bispecific CAR comprises an anti-CD20 antigen-binding region and an anti-CD19 antigen-binding region.
2. A vector comprising a nucleic acid, wherein the nucleic acid encodes a bispecific chimeric antigen receptor (CAR), wherein the bispecific CAR comprises an amino acid sequence set forth in SEQ ID NO: 16, and wherein the bispecific CAR comprises an anti-CD20 antigen-binding region and an anti-CD19 antigen-binding region.
3. A pharmaceutical composition comprising a vector, wherein the vector comprises a nucleic acid which encodes a bispecific chimeric antigen receptor (CAR), wherein the bispecific CAR comprises an amino acid sequence set forth in SEQ ID NO: 16, and wherein the bispecific CAR comprises an anti-CD20 antigen-binding region and an anti-CD19 antigen-binding region.
4. An immune cell comprising a nucleic acid, wherein the nucleic acid encodes a bispecific chimeric antigen receptor (CAR), wherein the bispecific CAR comprises an amino acid sequence set forth in SEQ ID NO: 16, and wherein the bispecific CAR comprises an anti-CD20 antigen-binding region and an anti-CD19 antigen-binding region.
5. A pharmaceutical composition comprising an immune cell, wherein the immune cell comprises a nucleic acid, wherein the nucleic acid encodes a bispecific chimeric antigen receptor (CAR), wherein the bispecific CAR comprises an amino acid sequence set forth in SEQ ID NO: 16, and wherein the bispecific CAR comprises an anti-CD20 antigen-binding region and an anti-CD19 antigen-binding region.
6. A nucleic acid, comprising a nucleic acid sequence set forth in SEQ ID NO: 18.
7. A vector comprising a nucleic acid, wherein the nucleic acid comprises a nucleic acid sequence set forth in SEQ ID NO: 18.
8. A pharmaceutical composition comprising a vector, wherein the vector comprises a nucleic acid, and wherein the nucleic acid comprises a nucleic acid sequence set forth in SEQ ID NO: 18.
9. An immune cell comprising a nucleic acid, wherein the nucleic acid comprises a nucleic acid sequence set forth in SEQ ID NO: 18.
10. A pharmaceutical composition comprising an immune cell, wherein the immune cell comprises a nucleic acid, wherein the nucleic acid comprises a nucleic acid sequence set forth in SEQ ID NO: 18.
Assignments (3)
CHANGE OF NAME
Recorded Jan 19, 2024
From: CELLULAR BIOMEDICINE GROUP, INC.
To: ABELZETA INC.
Reel/Frame 066356/0108 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 15, 2022
From: CELLULAR BIOMEDICINE GROUP HK LTD.
To: CELLULAR BIOMEDICINE GROUP INC.
Reel/Frame 062100/0469 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 14, 2022
From: YAO, YIHONG; LI, YANFENG; WEI, YUTIAN; ZHU, SHIGUI; YAO, XIN; HUANG, JIAQI
To: CELLULAR BIOMEDICINE GROUP HK LIMITED
Reel/Frame 060190/0482 →
Priority Claims (1)
CN 202010188038.1
· Mar 17, 2020
· national
Continuity (3)
References Cited (237)
US 6074841A
· Gearing et al.
· 2000
[cited by applicant]
US 6410319B1
· Raubitschek et al.
· 2002
[cited by applicant]
US 7446179B2
· Jensen et al.
· 2008
[cited by applicant]
US 7446190B2
· Sadelain et al.
· 2008
[cited by applicant]
US 7462352B2
· Hansen et al.
· 2008
[cited by applicant]
US 8287864B2
· Goldenberg et al.
· 2012
[cited by applicant]
US 8329181B2
· Martin et al.
· 2012
[cited by applicant]
US 8389282B2
· Sadelain et al.
· 2013
[cited by applicant]
US 8399645B2
· Campana et al.
· 2013
[cited by applicant]
US 8529902B2
· Teeling et al.
· 2013
[cited by applicant]
US 8906682B2
· June et al.
· 2014
[cited by applicant]
US 8911993B2
· June et al.
· 2014
[cited by applicant]
US 8916381B1
· June et al.
· 2014
[cited by applicant]
US 8975071B1
· June et al.
· 2015
[cited by applicant]
US 9101584B2
· June et al.
· 2015
[cited by applicant]
US 9102760B2
· June et al.
· 2015
[cited by applicant]
US 9102761B2
· June et al.
· 2015
[cited by applicant]
US 9328156B2
· June et al.
· 2016
[cited by applicant]
US 9447194B2
· Jensen
· 2016
[cited by applicant]
US 9464140B2
· June et al.
· 2016
[cited by applicant]
US 9481728B2
· June et al.
· 2016
[cited by applicant]
US 9499629B2
· June et al.
· 2016
[cited by applicant]
US 9518123B2
· June et al.
· 2016
[cited by applicant]
US 9540445B2
· June et al.
· 2017
[cited by applicant]
US 9605049B2
· Campana et al.
· 2017
[cited by applicant]
US 9662354B2
· Hyde et al.
· 2017
[cited by applicant]
US 9834590B2
· Campana et al.
· 2017
[cited by applicant]
US 9856322B2
· Campana et al.
· 2018
[cited by applicant]
US 9919061B2
· McDonagh et al.
· 2018
[cited by applicant]
US 20090148447A1
· Ledbetter
· 2009
[cited by applicant]
US 20110091473A1
· Golab
· 2011
[cited by applicant]
US 20130004480A1
· Parren
· 2013
[cited by applicant]
US 20140093454A1
· Teeling et al.
· 2014
[cited by applicant]
US 20140154253A1
· Ng
· 2014
[cited by applicant]
US 20160333108A1
· Forman
· 2016
[cited by applicant]
US 20180044415A1
· Escarpe
· 2018
[cited by applicant]
US 20180118823A1
· Thompson
· 2018
[cited by applicant]
US 20180258391A1
· June et al.
· 2018
[cited by applicant]
US 20180355318A1
· Delaney et al.
· 2018
[cited by applicant]
US 20190112380A1
· Chaudhary
· 2019
[cited by applicant]
US 20200040096A1
· Forman et al.
· 2020
[cited by applicant]
US 20200093861A1
· Klein et al.
· 2020
[cited by applicant]
US 20200306375A1
· Lobb et al.
· 2020
[cited by applicant]
US 20230104705A1
· Yao et al.
· 2023
[cited by applicant]
US 20230212255A1
· Yao et al.
· 2023
[cited by applicant]
US 20230242613A1
· Yao et al.
· 2023
[cited by applicant]
US 20240115605A1
· Yao et al.
· 2024
[cited by applicant]
US 20240139243A1
· Yao et al.
· 2024
[cited by applicant]
CN 101544694A
· 2009
[cited by applicant]
CN 108017717A
· 2018
[cited by applicant]
CN 108285486A
· 2018
[cited by applicant]
CN 109423495A
· 2019
[cited by applicant]
CN 109536455A
· 2019
[cited by applicant]
CN 109575143A
· 2019
[cited by applicant]
CN 110606893A
· 2019
[cited by applicant]
CN 112390891A
· 2021
[cited by applicant]
CN 112608387A
· 2021
[cited by applicant]
JP 2015092865A
· 2015
[cited by applicant]
JP 2018508215A
· 2018
[cited by applicant]
WO 2000023573A2
· 2000
[cited by applicant]
WO 2013123061A1
· 2013
[cited by applicant]
WO 2014012085A2
· 2014
[cited by applicant]
WO 2016014576A1
· 2016
[cited by applicant]
WO 2016097231A2
· 2016
[cited by applicant]
WO 2016100232A1
· 2016
[cited by applicant]
WO 2016126608A1
· 2016
[cited by applicant]
WO 2016139487A1
· 2016
[cited by applicant]
WO 2016166521A1
· 2016
[cited by applicant]
WO 2016179319A1
· 2016
[cited by applicant]
WO 2016201394A1
· 2016
[cited by applicant]
WO 2017025038A1
· 2017
[cited by applicant]
WO 2017149515A1
· 2017
[cited by applicant]
WO 2018067992A1
· 2018
[cited by applicant]
WO 2018121604A1
· 2018
[cited by applicant]
WO 2018145649A1
· 2018
[cited by applicant]
WO 2019028051A1
· 2019
[cited by applicant]
WO 2019075395A1
· 2019
[cited by applicant]
WO 2019126724A1
· 2019
[cited by applicant]
WO 2019128952A1
· 2019
[cited by applicant]
WO 2019129177A1
· 2019
[cited by applicant]
WO 2019154313A1
· 2019
[cited by applicant]
WO 2019206326A1
· 2019
[cited by applicant]
WO 2019210153A1
· 2019
[cited by applicant]
WO 2019223226A1
· 2019
[cited by applicant]
WO 2019232444A1
· 2019
[cited by applicant]
WO 2020010235A1
· 2020
[cited by applicant]
WO 2020033273A1
· 2020
[cited by applicant]
WO 2020061796A1
· 2020
[cited by applicant]
WO 2020072536A1
· 2020
[cited by applicant]
WO 2020151752A1
· 2020
[cited by applicant]
US 11,419,896 B2, 08/2022, Yao et al. (withdrawn)
[cited by applicant]
Belovezhec, Design and Comparative Analysis of CD20-Specific Chimeric Antigen Receptors. Proceedings of XIV International Conference of Students, Graduate Students and Young Scientists. Perspectives in Fundamental Scien…
[cited by applicant]
Budde et al., Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma. PLOS One. Dec. 17, 2013;8(12):e82742, …
[cited by applicant]
Buhler et al., Influence of structural variations on biological activity of anti-PSMA scFv and immunotoxins targeting prostate cancer. Anticancer Res. Sep. 2010;30(9):3373-9.
[cited by applicant]
Cao et al., Efficiency and safety of autologous chimeric antigen receptor T-cells therapy used for patients with lymphoma: A systematic review and meta-analysis. Medicine (Baltimore). Oct. 2019;98(42):e17506, 8 pages.
[cited by applicant]
Casan et al., Anti-CD20 monoclonal antibodies: reviewing a revolution. Hum Vaccin Immunother. 2018;14(12):2820-2841.
[cited by applicant]
Chavez et al., CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products. Ther Adv Hematol. Apr. 15, 2019;10:2040620719841581, 20 pages.
[cited by applicant]
Chow et al., Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy. Am J Hematol. Aug. 2019;94(8):E209-E213.
[cited by applicant]
Chuda et al., Ofatumumab: A Novel Anti-CD20 Monoclonal Antibody for the Treatment of Chronic Lymphocytic Leukemia. Current Drug Therapy. 2012;7:281-289.
[cited by applicant]
Dondelinger et al., Understanding the Significance and Implications of Antibody Numbering and Antigen-Binding Surface/Residue Definition. Front Immunol. Oct. 16, 2018;9:2278, 15 pages.
[cited by applicant]
Du et al., Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol. Jul. 2009;46(11-12):2419-23.
[cited by applicant]
Fesnak et al., Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer. Aug. 23, 2016;16(9):566-81.
[cited by applicant]
GenBank Accession No. AA022134, mh79f12.r1 Soares mouse placenta 4NbMP13.5 14.5 Mus musculus cDNA clone Image: 457199 5′ similar to SW:YBC6_YEAST P38203 Hypothetical 11.2 KD Protein in RPL19-MCM2 Intergenic Region. [2] …
[cited by applicant]
GenBank Accession No. AKH40187, C2B8, partial [synthetic construct]. 7 pages, Jul. 28, 2015.
[cited by applicant]
GenBank Accession No. AMZ04820, bi-specific chimeric antigen receptor 20-19 Long, partial [synthetic construct]. 10 pages, Apr. 24, 2016.
[cited by applicant]
GenBank Accession No. AMZ04821.1, bi-specific chimeric antigen receptor 20-19 Short, partial [synthetic construct]. 1 page, Apr. 24, 2016.
[cited by applicant]
GenBank Accession No. ANS59202, Dsg3 EC1-3 CAAR [synthetic construct]. 2 pages, Jul. 19, 2016.
[cited by applicant]
GenBank Accession No. KX000911, Synthetic construct bi-specific chimeric antigen receptor (EAAAK)3 20-19 Short gene, partial cds. 2 pages, Apr. 24, 2016.
[cited by applicant]
Ghafouri et al., CD19/CD20 bispecific chimeric antigen receptor (CAR) in naive/memory T-cells for the treatment of relapsed or refractory B-cell lymphomas. Jul. 1, 2021;81(13):Abstract CT007.
[cited by applicant]
Hallek, Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol. Sep. 2017;92(9):946-965.
[cited by applicant]
Hamdy et al., Sheep red blood cells armed with anti-CD20 single-chain variable fragments (scFvs) fused to a glycosylphosphatidylinositol (GPI) anchor: a strategy to target CD20-positive tumor cells. J Immunol Methods. F…
[cited by applicant]
Jabbour et al., Monoclonal antibodies in acute lymphoblastic leukemia. Blood. Jun. 25, 2015; 125(26):4010-6.
[cited by applicant]
Jensen et al., CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy. Biol Blood Marrow Transplant. 1998;4(2):75-83.
[cited by applicant]
Jonnalagadda et al., Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. Mol Ther. Apr. 2015;23(4):757-68.
[cited by applicant]
Kim et al., Improving the productivity of single-chain Fv antibody against c-Met by rearranging the order of its variable domains. J Microbiol Biotechnol. Jun. 2008; 18(6):1186-90.
[cited by applicant]
Kipriyanov et al., Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies. J Mol Biol. Jun. 27, 2003;330(1):99-111.
[cited by applicant]
Korycka-Wolowiec et al., Ofatumumab for treating chronic lymphocytic leukemia: a safety profile. Expert Opin Drug Saf. 2015;14(12):1945-59.
[cited by applicant]
Ku et al., Tumour cell surface antigen targeted therapies in B-cell lymphomas: Beyond rituximab. Blood Rev. Jan. 2017;31(1):23-35.
[cited by applicant]
Kunik et al., Structural consensus among antibodies defines the antigen binding site. PLoS Comput Biol. 2012;8(2):e1002388.
[cited by applicant]
Kussie et al., A single engineered amino acid substitution changes antibody fine specificity. J Immunol. Jan. 1, 1994;152(1):146-52.
[cited by applicant]
Lin, Ofatumumab: a novel monoclonal anti-CD20 antibody. Pharmgenomics Pers Med. 2010;3:51-9.
[cited by applicant]
Liu et al., Fine mapping of the antigen-antibody interaction of scFv215, a recombinant antibody inhibiting RNA polymerase II from
[cited by applicant]
Lopez-Atalyaya et al., Development and maintenance of the brain's immune toolkit: Microglia and non-parenchymal brain macrophages. Dev Neurobiol. Jun. 2018;78(6):561-579.
[cited by applicant]
Lulla et al., The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma. Clin Adv Hematol Oncol. May 2018;16(5):375-386.
[cited by applicant]
Makita et al., Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Cancer Sci. Jun. 2017;108(6):1109-1118.
[cited by applicant]
Martyniszyn et al., CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies. Hum Gene Ther. Dec. 2017;28(12):1147-1157.
[cited by applicant]
Nakagawa et al.,
[cited by applicant]
Panka et al., Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies. Proc Natl Acad Sci U S A. May 1988;85(9):3080-4.
[cited by applicant]
Patel et al., Expanding the Role of CAR-T Cell Therapy to Systemic Lupus Erythematosus. EMJ Hematol. 2020;8(1):105-112.
[cited by applicant]
Ramos et al., CAR-T Cell Therapy for Lymphoma. Annu Rev Med. 2016;67:165-83.
[cited by applicant]
Riaz et al., Anti-CD 19 and anti-CD 20 CAR-modified T cells for B-cell malignancies: a systematic review and meta-analysis. Immunotherapy. Sep. 2017;9(12):979-993.
[cited by applicant]
Rudikoff et al., Single amino acid substitution altering antigen-binding specificity. Proc Natl Acad Sci U S A. Mar. 1982;79(6):1979-83.
[cited by applicant]
Rufener et al., Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab. Cancer Immunol Res. Jun. 2016;4(6):509-19.
[cited by applicant]
Sela-Culang et al., The structural basis of antibody-antigen recognition. Front Immunol. Oct. 8, 2013;4:302.
[cited by applicant]
Shah et al., Bispecific anti-CD20, anti-CD19 Car T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med. Oct. 2020;26(10):1569-1575.
[cited by applicant]
Shetty et al., Liver sinusoidal endothelial cells—gatekeepers of hepatic immunity. Nat Rev Gastroenterol Hepatol. Sep. 2018;15(9):555-567.
[cited by applicant]
Teeling et al., Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood. Sep. 15, 2004;104(6):1793-800.
[cited by applicant]
Teeling et al., The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. Jul. 1, 2006;177(1):362-71.
[cited by applicant]
Till et al., Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. Sep. 15, 2008;112(6):2261-71.
[cited by applicant]
Till et al., CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood. Apr. 26, 2012;119(17):3940-50.
[cited by applicant]
Wang et al., Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. Clin Immunol. Dec. 2014;155(2):160-75.
[cited by applicant]
Schneider et al: “A tandem CD19/CD20 Car lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines”, Journal for Immunotherapy of Cancer, vol. 5, No. 1, 2017, pp. 1-17.
[cited by applicant]
Chuan et al: Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B cell lymphoma, Blood, 2020, 136(14):1632-1644.
[cited by applicant]
Liang et al: “Safety and efficacy of a novel anti-CD20/CD19 bi-specific CAR T-cell therapy (C-CAR039) in relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL).”, Journal of Clinical Oncology, vol. 39, No. 15_…
[cited by applicant]
U.S. Appl. No. 17/475,766, filed Sep. 15, 2021, U.S. Pat. No. 11,439,665, Issued.
[cited by applicant]
U.S. Appl. No. 17/750,658, filed May 23, 2022, U.S. Pat. No. 11,633,430, Issued.
[cited by applicant]
U.S. Appl. No. 17/911,502, filed Sep. 14, 2022, 2023-0104705, Published.
[cited by applicant]
U.S. Appl. No. 17/911,524, filed Sep. 14, 2022, 2023-0212255, Published.
[cited by applicant]
U.S. Appl. No. 18/183,681, filed Mar. 14, 2023, 2024-0139243, Published.
[cited by applicant]
U.S. Appl. No. 16/877,069, filed May 18, 2020, U.S. Pat. No. 11,207,349, Issued.
[cited by applicant]
U.S. Appl. No. 16/484,482, filed Aug. 8, 2019, U.S. Pat. No. 11,066,457, Issued.
[cited by applicant]
U.S. Appl. No. 17/352,915, filed Jun. 21, 2021, U.S. Pat. No. 11,472,858, Issued.
[cited by applicant]
U.S. Appl. No. 17/723,859, filed Apr. 19, 2022, U.S. Pat. No. 11,618,778, Issued.
[cited by applicant]
U.S. Appl. No. 17/750,855, filed May 23, 2022, U.S. Pat. No. 11,608,369, Issued.
[cited by applicant]
U.S. Appl. No. 17/831,637, filed Jun. 3, 2022, 2022-0340640, Published.
[cited by applicant]
U.S. Appl. No. 18/173,187, filed Feb. 23, 2023, 2023-0242613, Published.
[cited by applicant]
U.S. Appl. No. 18/263,050, filed Jul. 26, 2023, 2024-0115605, Published.
[cited by applicant]
Wark et al., Latest technologies for the enhancement of antibody affinity. Adv Drug Deliv Rev. Aug. 7, 2006;58 (5-6):657-70.
[cited by applicant]
Watanabe et al., Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ? chimeric antigen receptor-modified effector CD8+ T cells. J Immunol. Feb. 1, 2015;194(3):911-20.
[cited by applicant]
Wong et al., Structural requirements for a specificity switch and for maintenance of affinity using mutational analysis of a phage-displayed anti-arsonate antibody of Fab heavy chain first complementarity-determining re…
[cited by applicant]
Wu et al., Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange. Protein Eng. Dec. 2001;14(12):1025-33.
[cited by applicant]
Zah et al., Addendum: T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells. Cancer Immunol Res. Jul. 2016;4(7):639-41.
[cited by applicant]
Zah et al., T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells. Cancer Immunol Res. Jun. 2016;4(6):498-508.
[cited by applicant]
Zhang et al., Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase lla trial report. Signal Transduct Target Ther. Mar…
[cited by applicant]
Zhou et al., The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor-T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis. BMC Cancer. Sep. 26, 2018;18(1):929, 13 pages.
[cited by applicant]
Zhu et al., Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center. Cytotherapy. Mar. 2018;20(3):394-406.
[cited by applicant]
European Office Action for Application No. 18751050.8, dated Oct. 15, 2020, 14 pages.
[cited by applicant]
International Search Report and Written Opinion for Application No. PCT/CN2020/109645, dated Dec. 16, 2020, 15 pages.
[cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2021/022779, dated Aug. 9, 2021, 16 pages.
[cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2022/013875, dated Jul. 8, 2022, 10 pages.
[cited by applicant]
International Search Report and Written Opinion for Application No. PCT/CN2018/075867, dated May 9, 2018, 14 pages.
[cited by applicant]
ClinicalTrials.gov, NCT03019055, Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell. 15 pages, Jul. 27, 2023.
[cited by applicant]
Li et al., Clinical Responses and Pharmacokinetics of fully human BCMA Targeting Car T Cell Therapy in Relapsed/Refractory Multiple Myeloma. 17th International Myeloma Workshop. pp. e23-e24, Abstract 0AB-033, Sep. 12-15…
[cited by applicant]
Raje et al., Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med. May 2, 2019;380(18):1726-1737.
[cited by applicant]
Cited By (1)